Journal
LIFE SCIENCES
Volume 87, Issue 5-6, Pages 147-153Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2010.06.004
Keywords
Diabetic nephropathy; Rats; Rosiglitazone; Sirolimus; Streptozotocin
Funding
- ISCIII/FIS [PI060582]
- Red de Investigacion Renal (REDinREN) [ISCIII 06/0016]
- ISCIII [INT 08/059]
- Department of Health of the Generalitat de Catalunya
- IDIBELL
Ask authors/readers for more resources
Aims: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists and mammalian target of rapamycin (mTOR) inhibitors share mechanisms concerning cell growth and reduction of extracellular matrix accumulation. The purpose of this study was to evaluate the potential synergistic effect of this combination on diabetic kidney disease in rats. Main methods: Diabetes was induced by streptozotocin in 42 male Sprague-Dawley rats. Sixteen weeks after diabetes induction, animals were divided into four groups: diabetic animals without intervention (D), diabetic animals with administration of sirolimus (D + SRL), diabetic animals with administration of rosiglitazone (D + RGT), and diabetic animals with administration of sirolimus and rosiglitazone (D + SRL + RGT). Key findings: At a 30-day follow up, diabetic rats showed higher kidney weight, mean glomerular volume, mesangial expansion and albuminuria compared with non-diabetic rats. mTOR downstream proteins, p-T389-S6K and p-T37/46-4EBP1, were higher in diabetic than non-diabetic kidneys, whereas p-S473-AKT was not, suggesting that hyperglycemia mainly activated the mTORC1 pathway in vivo. Moreover, the catalytic subunit of protein phosphatase 2A (PP2Ac) was down-regulated in the diabetic kidney. Sirolimus inhibited the mTORC1 pathway, while the PPAR-gamma agonist rosiglitazone enhanced PP2Ac and reduced p7056K. Both drugs were associated with a reduction in albuminuria, renal enlargement and mesangial expansion, but without any improvement in glycemic control. Sirolimus and rosiglitazone in combination down-regulated the mTORC1 pathway and over-activated PP2Ac in diabetic kidney. This effect may account for the synergistic reduction of renal hypertrophy, albuminuria and renal TGF-beta 1 observed in diabetic rats treated with SRL + RGT. Significance: The combination of sirolimus and rosiglitazone is renoprotective with respect to diabetic nephropathy. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available